Natera, Inc.: Is The Recent Growth in Signatera Volumes Here To Stay?

Natera, Inc. reported strong financial results for the first quarter of 2025, highlighting significant revenue growth and operational achievements, which present a mixed yet promising outlook for potential investors. The company reported a notable increase in revenue to $502 million, up 37% from $368 million in the same period last year. This growth was driven by high demand across multiple product lines, particularly within women’s health and the oncology segment, where Signatera clinical volumes grew by 52% year-on-year. The company’s broad portfolio, including products like Signatera and Prospera, continues to sustain impressive growth metrics and enhance Natera’s positioning in the clinical diagnostics sector.